PredxBio today announced the official launch of enhanced SpaceIQ™ platform to integrate brightfield, spatial proteomics and transcriptomics datasets to deliver a unified, high-resolution view of the tumor microenvironment—unlocking new insights into cellular interactions, immune architecture, and mechanisms of therapeutic response and resistance. This milestone launch, timed ahead of the American Association for Cancer Research (AACR) Annual Meeting 2025, will be highlighted by two scientific poster presentations and a spotlight symposium at the conference. The new capabilities of SpaceIQ™ are poised to accelerate insights in cancer biology, improve patient stratification, and drive advances in precision immuno-oncology.
PITTSBURGH, April 25, 2025 /PRNewswire-PRWeb/ -- PredxBio today announced the official launch of enhanced SpaceIQ™ platform to integrate brightfield, spatial proteomics and transcriptomics datasets to deliver a unified, high-resolution view of the tumor microenvironment—unlocking new insights into cellular interactions, immune architecture, and mechanisms of therapeutic response and resistance. This milestone launch, timed ahead of the American Association for Cancer Research (AACR) Annual Meeting 2025, will be highlighted by two scientific poster presentations and a spotlight symposium at the conference. The new capabilities of SpaceIQ™ are poised to accelerate insights in cancer biology, improve patient stratification, and drive advances in precision immuno-oncology.
SpaceIQ™ is an explainable AI-driven spatial multiomics platform that provides a rigorous framework to interrogate the tumor microenvironment. With its latest upgrade, SpaceIQ™ can now ingest and co-analyze brightfield, spatial proteomics and transcriptomics datasets from tumor samples. Researchers are able to map gene expression profiles onto tissue architecture and identify complex cellular neighborhoods (or "microdomains") that drive tumor progression and immune evasion. By leveraging probabilistic modeling and unbiased cell typing, SpaceIQ™ uncovers transition cell states, cell–cell interactions, and mechanistic pathway networks within the tumor – yielding a deeper understanding of tumor heterogeneity and therapy resistance.
"PredxBio's unique capabilities in unbiased cell typing and explainable AI allow us to decode the mechanistic complexities of the tumor microenvironment," said S. Chakra Chennubhotla, PhD, Chief of AI at PredxBio. "By integrating multiomic spatial data with SpaceIQ™, we are advancing the frontier of precision oncology – translating these insights into actionable solutions for patient care."
At AACR 2025 in Chicago, PredxBio and its collaborators will present two new studies showcasing SpaceIQâ„¢'s impact:
- Poster 1 (Abstract #2485): "A Bayesian Framework for Unraveling Disease Biology from Spatially Resolved Single-Cell Omics Datasets." Co-authored in collaboration with Arutha Kulasinghe, PhD, Director of the Queensland Spatial Biology Centre, this poster introduces a novel Bayesian approach for analyzing high-dimensional spatial single-cell data. Presentation Time: April 28, 2025, 9:00 AM–12:00 PM CT (Poster Section 47, Board #6). The study demonstrates how combining unbiased computational methods with biological priors in SpaceIQ™ can reveal emergent cell types and microdomains, offering new insights into disease mechanisms.
- Poster 2 (Abstract #5317): "Multimodal Spatial Analysis of Colon Cancer Tissue Reveals Emergence of an Immunosuppressive Tumor Maintenance Mechanism." Co-authored by Gaurav N. Joshi, PhD, and colleagues from Nikon BioImaging Lab in Boston, this research applies SpaceIQ™ to a colon cancer sample by integrating mIF and spatial transcriptomics. Presentation Time: April 29, 2025, 2:00 PM–5:00 PM CT (Poster Section 8, Board #23). This study uncovers how tumor and immune cells are spatially organized to create an immunosuppressive microenvironment that supports tumor maintenance.
"Using SpaceIQ's multiomic analysis, we discovered an immunosuppressive mechanism in colon cancer that would have been difficult to detect with single-modality data," noted Gaurav N. Joshi, PhD, lead author of the colon cancer study. "By combining brightfield, spatial proteomics and transcriptomics datasets, we can see how different immune cells and signals interact within the tumor microenvironment. This level of insight is invaluable for precision immuno-oncology, as it points to biomarkers and therapeutic targets that can inform more effective, personalized treatments."
Spotlight Symposium at AACR 2025
The launch of SpaceIQâ„¢ will also be highlighted during a Spotlight Theater Symposium titled:
"Harnessing Spatial Multiomic Biomarkers: Ushering in a New Era of Precision Oncology"
- Date: Sunday, April 27, 2025
- Time: 3:30 PM – 4:30 PM CT
- Location: Spotlight Theater D, McCormick Place, Chicago
The session will begin with a joint presentation by B. Dusty Majumdar, PhD, S. Chakra Chennubhotla, PhD, and A/Prof. Arutha Kulasinghe, followed by a panel discussion featuring spatial biology experts from academia and industry. Attendees will hear how SpaceIQâ„¢ can be applied to decode tumor complexity and guide biomarker discovery, patient stratification, and companion diagnostic development.
Visit PredxBio at AACR 2025
- Exhibit Booth: #3252
- Conference Dates: April 26–30, 2025
- Venue: McCormick Place, Chicago, IL
Attendees are invited to stop by the booth for hands-on demonstrations and to learn how SpaceIQâ„¢ is enabling faster, more informed decisions in drug development, biomarker discovery, and patient stratification.
About PredxBio
PredxBio is a spatial analytics company headquartered in Pittsburgh, PA, powering next-generation cancer therapeutics with its AI-driven spatial biomarkers. PredxBio's proprietary approaches delve into the mechanism of action of drugs and predict patient outcomes with over 90% accuracy. By transforming multiplexed biopsy images and multi-modal spatial data into actionable insights – and revealing the network biology of cancer – PredxBio is setting new standards for biomarker discovery and clinical research. In partnership with leading pharmaceutical companies and research institutions, PredxBio is accelerating drug discovery and advancing personalized medicine to impact cancer patients globally. For more information, visit
Media Contact
A. Burak Tosun, PredxBio, 1 4122123115, [email protected],
SOURCE PredxBio
Share this article